We are live on ! Find out more
WHWK

Whitehawk Therapeutics
WHWK

Fund managers haven’t disclosed any holdings of WHWK yet.

WHWK Hedge Fund Activity: Q1 2026 in Review

62 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q1 2026, worth a combined $119M — up 51% from $79.2M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new WHWK positions and 6 closed out — a net gain of 15 holders — while 15 added to existing stakes and 8 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.72M. The largest seller was Stempoint Capital, cutting an estimated $1.63M.

  • 62 institutional investors held Whitehawk Therapeutics (WHWK) as of Q1 2026, up from 48 in Q4 2025.
  • Funds reported $119M of Whitehawk Therapeutics stock for Q1 2026, up 51% quarter-over-quarter.
  • 21 funds opened new Whitehawk Therapeutics positions in Q1 2026 and 6 closed out, a net change of +15 holders.
  • The largest Whitehawk Therapeutics buyer in Q1 2026 was Balyasny Asset Management, an estimated $1.72M added.
  • The largest Whitehawk Therapeutics seller in Q1 2026 was Stempoint Capital, an estimated $1.63M sold.

Based on aggregated 13F filings for Q1 2026.